293 related articles for article (PubMed ID: 16364753)
1. Replication-defective viruses as vaccines and vaccine vectors.
Dudek T; Knipe DM
Virology; 2006 Jan; 344(1):230-9. PubMed ID: 16364753
[TBL] [Abstract][Full Text] [Related]
2. New viral vectors for infectious diseases and cancer.
Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
4. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
5. Defective interfering viruses and their impact on vaccines and viral vectors.
Frensing T
Biotechnol J; 2015 May; 10(5):681-9. PubMed ID: 25728309
[TBL] [Abstract][Full Text] [Related]
6. Self-Amplifying RNA Viruses as RNA Vaccines.
Lundstrom K
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698494
[TBL] [Abstract][Full Text] [Related]
7. Immunization by Replication-Competent Controlled Herpesvirus Vectors.
Bloom DC; Tran RK; Feller J; Voellmy R
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899091
[TBL] [Abstract][Full Text] [Related]
8. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
[TBL] [Abstract][Full Text] [Related]
9. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
10. Construction and evaluation of genetically engineered replication-defective porcine reproductive and respiratory syndrome virus vaccine candidates.
Welch SK; Jolie R; Pearce DS; Koertje WD; Fuog E; Shields SL; Yoo D; Calvert JG
Vet Immunol Immunopathol; 2004 Dec; 102(3):277-90. PubMed ID: 15507311
[TBL] [Abstract][Full Text] [Related]
11. Highly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expression.
Holzer GW; Remp G; Antoine G; Pfleiderer M; Enzersberger OM; Emsenhuber W; Hämmerle T; Gruber F; Urban C; Falkner FG; Dorner F
J Virol; 1999 Jun; 73(6):4536-42. PubMed ID: 10233911
[TBL] [Abstract][Full Text] [Related]
12. Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG).
Kim MS; Kim KH
Fish Shellfish Immunol; 2019 May; 88():231-236. PubMed ID: 30817994
[TBL] [Abstract][Full Text] [Related]
13. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
14. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
Volz A; Sutter G
Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
[TBL] [Abstract][Full Text] [Related]
15. A proposed treatment for pathogenic enveloped viruses having high rates of mutation or replication.
Roe K
Scand J Immunol; 2020 Sep; 92(3):e12928. PubMed ID: 32640050
[TBL] [Abstract][Full Text] [Related]
16. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.
Virnik K; Ni Y; Berkower I
Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312
[TBL] [Abstract][Full Text] [Related]
17. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
[TBL] [Abstract][Full Text] [Related]
18. Recombinant viruses as vaccines against viral diseases.
Souza AP; Haut L; Reyes-Sandoval A; Pinto AR
Braz J Med Biol Res; 2005 Apr; 38(4):509-22. PubMed ID: 15962176
[TBL] [Abstract][Full Text] [Related]
19. Vaccination of Macaques with DNA Followed by Adenoviral Vectors Encoding Simian Immunodeficiency Virus (SIV) Gag Alone Delays Infection by Repeated Mucosal Challenge with SIV.
Almond N; Berry N; Stebbings R; Preston M; Ham C; Page M; Ferguson D; Rose N; Li B; Mee ET; Hassall M; Stahl-Hennig C; Athanasopoulos T; Papagatsias T; Herath S; Benlahrech A; Dickson G; Meiser A; Patterson S
J Virol; 2019 Nov; 93(21):. PubMed ID: 31413132
[TBL] [Abstract][Full Text] [Related]
20. Viral vectors for veterinary vaccines.
Sheppard M
Adv Vet Med; 1999; 41():145-61. PubMed ID: 9890015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
